Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to use non-invasive Magnetic Resonance Imaging (MRI) scans to investigate venous insufficiency, brain iron levels and white matter hyperintensities (WMHs) to determine if there is direct correlation with Idiopathic Parkinson's Disease (IPD).

Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease after Alzheimer's disease and it affects roughly 0.1% to 0.3% of the population. The risk of having IPD increases with age and the median onset age is about 60 years. The etiology of IPD remains unknown. Generally, Parkinson's patients show a reduction of dopamine levels in the deep grey matter of the brain over time. Many clinically diagnosed cases of IPD are associated with white matter hyperintensities (WMH) and elevated brain iron levels. Furthermore, in the last few years there has been an increasing interest in the role of veins in neurodegenerative diseases. More attention has been paid to the extracranial veins as being potential sources of venous hypertension. The obstructed veins are thought to cause venous insufficiency. By using MRI techniques, the investigators can not only obtain qualitative vascular information but also quantitative arterial and venous blood flow measurements.


Clinical Trial Description

Experimental plans: All patients and controls will consent to be subjects in this study. Data will be collected on the Siemens Skyra 3T scanner at the University of Saskatchewan using a 16 channel head/neck coil arrangement. The investigators main approach in this research is to collect MR data on the vasculature in the brain and neck, the iron content in the brain, and standard anatomical scans for 20 patients with idiopathic Parkinson's disease and 10 age matched normal subjects. MR venography, flow quantification and susceptibility weighted imaging will be used.

Anatomic MR venography (MRV): Contrast enhanced MRV is widely regarded as the optimal method for evaluation of disease involving the dural venous sinuses. It is an accurate, reliable and robust method for assessing sino-venous pathology such as thrombosis and tumor invasion. MRV is also able to demonstrate pathology involving larger cerebral veins. The investigators will be able to record both anatomic variants as well as any stenosis. Extracranially, the investigators will look for any significant variants or stenosis affecting the jugular venous system, the vertebral venous system and the azygous system. Data will be analyzed to separately display and evaluate the structure of arteries and veins in the head and neck. The maximum intensity projection (MIP) of the whole series will be generated in the coronal view. The major arteries will be evaluated as well as major veins of interest for the structural analysis including the transverse sinuses, the internal and external jugular veins, vertebral veins and deep cervical veins which usually serve as collaterals in case of flow abnormalities in the jugular veins. Cross sectional areas (CSA) of suspicious stenotic regions will also be measured to validate whether the variation seen in these CSA are veins stenosis or not.

Flow quantification (FQ): Pathological change in cerebrospinal venous drainage will be reflected by upstream disturbance of venous flow. Phase contrast MR flow techniques allow the investigators to interrogate venous flow. By applying FQ techniques to the dural venous sinuses, investigators hope to characterize the interplay between anatomic venous obstruction and pathologically altered drainage. By understanding this relationship, the investigators can gain deeper insight into the mechanism by which cerebrospinal venous insufficiency interacts with iron homeostasis mechanisms and ultimately with the pathogenesis of Parkinson's disease. Dural sinus hemodynamics can be studied non-invasively with phase contrast FQ. The phase contrast flow quantification (PCFQ) images will be used to analyze the through-plane cerebral spinal fluid in the neck (C2/C3 level), as well as blood flow in the neck (C2/C3 and C6/C7 levels), the superior sagittal sinus (SSS), both left and right transverse sinus, the straight sinus, both the extra cranial jugular and vertebral veins and Dural Sinus. Areas of interest will be drawn around the veins and arteries of interest and flow will be calculated over a full cardiac cycle. Thirty time points will be collected for each cardiac cycle by using a retroactive pulse trigger. The vessels of interest will include: the internal and external jugular veins (IJVs, EJVs), vertebral veins, deep cervical veins, common carotid arteries and vertebral arteries. The investigators will be evaluating the integrated flow, the average velocity, the volume flow rate, as well as negative and positive flow rate. This will be assessed in the cervical arteries to compare the inflow and outflow of the brain. Abnormalities may be identified by stressing the system, i.e., with a breath hold. Finally a large number of quantitative measures will be made on all the arteries and veins in the neck to assess both individual variants and total flow in the brain.

Measuring Iron in the basal ganglia and thalamus using Susceptibility Weighted Imaging (SWI): A presence of iron not only in lesions, but now more importantly in the basal ganglia and thalamus has been shown in IPD patients. The latter shows iron build up at the confluence of the draining veins in these areas. SWI can be run to show iron deposition in several areas of interest within the brain. SWI has very high spatial resolution and is an optimal method to study the small internal cerebral venous system. The ability to measure the amount of non-heme iron in the brain will facilitate a better understanding of the disease progression and may help in predicting the treatment outcome. Iron deposition will be evaluated from the SWI images. To measure iron content in grey matter, investigators will look at iron in the following eight regions: caudate nucleus, globus pallidus, putamen, thalamus, pulvinar thalamus (as it appears to be affected much before the rest of the thalamus), substantia nigra, red nucleus and dentate nucleus. For each deep gray matter structure, two major regions of interest will be analyzed: the entire object drawn manually and the region-of-interest that has much higher iron content. The investigators will provide the following information for these regions: iron content in the abnormal part of the structure (the investigators refer to this as the high iron content region); the area of this region; the average iron per pixel in this region; and also the investigators will quote the same three values for the total iron in these structures. ;


Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02045420
Study type Observational
Source University of Saskatchewan
Contact
Status Active, not recruiting
Phase N/A
Start date December 2013
Completion date March 2017

See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT05107531 - Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease Phase 2
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease